BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 7533697)

  • 1. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis.
    Bryson HM; Sorkin EM
    Drugs; 1994 Dec; 48(6):894-906. PubMed ID: 7533697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
    Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
    J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.
    Goa KL; Lamb H
    Pharmacoeconomics; 1997 Sep; 12(3):409-22. PubMed ID: 10170464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dornase alfa for cystic fibrosis.
    Yang C; Chilvers M; Montgomery M; Nolan SJ
    Cochrane Database Syst Rev; 2016 Apr; 4():CD001127. PubMed ID: 27043279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dornase alfa for cystic fibrosis.
    Yang C; Montgomery M
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD001127. PubMed ID: 33735508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dornase alfa for cystic fibrosis.
    Yang C; Montgomery M
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD001127. PubMed ID: 30187450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dornase alfa: a new option in the management of cystic fibrosis.
    Witt DM; Anderson L
    Pharmacotherapy; 1996; 16(1):40-8. PubMed ID: 8700791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
    McCoy K; Hamilton S; Johnson C
    Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Respiratory evolution of patient with mucoviscidosis treated with mucolytic agents plus dornase alfa].
    Derelle J; Bertolo-Houriez E; Marchal F; Weber M; Virion JM; Vidailhet M
    Arch Pediatr; 1998 Apr; 5(4):371-7. PubMed ID: 9759155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of dornase alfa in the treatment of cystic fibrosis.
    Cramer GW; Bosso JA
    Ann Pharmacother; 1996 Jun; 30(6):656-61. PubMed ID: 8792953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.
    Johnson CA; Butler SM; Konstan MW; Breen TJ; Morgan WJ
    J Pediatr; 1999 Jun; 134(6):734-9. PubMed ID: 10356143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled mannitol for cystic fibrosis.
    Nevitt SJ; Thornton J; Murray CS; Dwyer T
    Cochrane Database Syst Rev; 2020 May; 5(5):CD008649. PubMed ID: 32358807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period.
    Shah PL; Conway S; Scott SF; Rainisio M; Wildman M; Stableforth D; Hodson ME
    Respiration; 2001; 68(2):160-4. PubMed ID: 11287830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dornase alfa for cystic fibrosis.
    Jones AP; Wallis C
    Cochrane Database Syst Rev; 2010 Mar; (3):CD001127. PubMed ID: 20238314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dornase alfa in early cystic fibrosis lung disease.
    Robinson PJ
    Pediatr Pulmonol; 2002 Sep; 34(3):237-41. PubMed ID: 12203856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group.
    Geller DE; Eigen H; Fiel SB; Clark A; Lamarre AP; Johnson CA; Konstan MW
    Pediatr Pulmonol; 1998 Feb; 25(2):83-7. PubMed ID: 9516090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
    Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
    Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled mannitol for cystic fibrosis.
    Nevitt SJ; Thornton J; Murray CS; Dwyer T
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD008649. PubMed ID: 29424930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.
    Fitzgerald DA; Hilton J; Jepson B; Smith L
    Pediatrics; 2005 Oct; 116(4):e549-54. PubMed ID: 16147970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.